Case Report: Herceptin as a Potentially Valuable Adjuvant Therapy for a Patient With Human Epidermal Growth Factor Receptor 2-Positive Advanced Esophageal Squamous Cell Carcinoma

Han, Lei; Chi, Pan; Ni, Qingtao; Tao, Yu

doi:10.3389/fonc.2020.600459

Cited by 2 publications

(2 citation statements)

References 26 publications

(29 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Trastuzumab, commercially known as Herceptin, is a Roche-developed HER2-targeted therapy that can directly treat HER2+ cancer cells, which are commonly overexpressed in breast and stomach cancer and have also been suggested to be present in esophageal cancer [ 74 ]. In EAC specifically, however, the literature has suggested that the presence of HER2+ in EAC ranges between 15% and 29% [ 75 ].…”

Section: Druggable Targetsmentioning

confidence: 99%

Biomarkers for Early Detection, Prognosis, and Therapeutics of Esophageal Cancers

Rai

Abdo

Agrawal

2023

IJMS

View full text Add to dashboard Cite

Esophageal cancer (EC) is the deadliest cancer worldwide, with a 92% annual mortality rate per incidence. Esophageal squamous cell carcinoma (ESCC) and esophageal adenocarcinoma (EAC) are the two major types of ECs, with EAC having one of the worst prognoses in oncology. Limited screening techniques and a lack of molecular analysis of diseased tissues have led to late-stage presentation and very low survival durations. The five-year survival rate of EC is less than 20%. Thus, early diagnosis of EC may prolong survival and improve clinical outcomes. Cellular and molecular biomarkers are used for diagnosis. At present, esophageal biopsy during upper endoscopy and histopathological analysis is the standard screening modality for both ESCC and EAC. However, this is an invasive method that fails to yield a molecular profile of the diseased compartment. To decrease the invasiveness of the procedures for diagnosis, researchers are proposing non-invasive biomarkers for early diagnosis and point-of-care screening options. Liquid biopsy involves the collection of body fluids (blood, urine, and saliva) non-invasively or with minimal invasiveness. In this review, we have critically discussed various biomarkers and specimen retrieval techniques for ESCC and EAC.

show abstract

Section: Druggable Targetsmentioning

confidence: 99%

Biomarkers for Early Detection, Prognosis, and Therapeutics of Esophageal Cancers

Rai

Abdo

Agrawal

2023

IJMS

View full text Add to dashboard Cite

show abstract

“…7,8 Traditional standard first-line therapy for advanced or metastatic esophageal cancer is doublet platinumbased chemotherapy with median overall survival (OS) about 1 year, [9][10][11][12][13][14][15] while combining human epidermal growth factor receptor 2 (HER2) antibody with the standard chemotherapy is recommended for HER2 positive GAC. 16 A case report demonstrated the promising treatment effect of adding anti-HER2 to chemotherapy in HER2-positive ESCC, 17 but relevant randomized trials are lacking largely due to the very low HER2positive rate in ESCC. 18,19 There is no evidence that targeted therapies are of clinical significance in phase III trials regarding advanced or metastatic ESCC.…”

mentioning

confidence: 99%

Chemoimmunotherapy for esophageal squamous cell carcinoma—Summary and discussion of recent clinical trials

Zhang

Huang

et al. 2023

MedComm – Future Medicine

View full text Add to dashboard Cite

As a kind of carcinoma with increasing morbidity, poor prognosis, and high mortality, esophageal squamous cell carcinoma (ESCC) is challenging for clinical management. Chemotherapy has been the standard treatment for ESCC over decades, while its clinical outcomes remain unsatisfying. And the regimen that combine standard chemotherapy with targeted therapy also demonstrates little effect. However, the advent of immune checkpoint inhibitors (ICI) proved to be a game changer in cancer treatment. Recent clinical trials had sprung up to evaluate the combined effect of ICI and chemotherapy regarding first‐line ESCC treatment. What's more, researchers attempt to explore the possibility to implement ICI monotherapy regarding second‐line ESCC treatment. In conclusion, most of the first‐line trails present inspiring achievement, while ICI monotherapy indicates little improvement for ESCC treatment. To point out the heterogenicity that could be the potential reasons biasing the pooled results, the differences of PD‐L1 immunohistochemistry (IHC) assays, geographic regions, chemotherapy regimens, and sex disparity among these trails are discussed respectively. In addition, the adverse events occurred during the trails are summarized, which confirm the safety of immunotherapy and chemoimmunotherapy. The article comprehensively reviews the representative explorations of using chemoimmunotherapy strategies in ESCC, as well as the deficiencies among them. Moreover, we highlight some feasible approaches. It will be beneficial for conducting more precise clinical trials on chemoimmunotherapy for ESCC in the future, including the use of more appropriate PD‐L1 IHC assays, careful consideration of the heterogeneity of the enrolled population and the optimal combination of chemotherapy and ICI.

show abstract

Case Report: Herceptin as a Potentially Valuable Adjuvant Therapy for a Patient With Human Epidermal Growth Factor Receptor 2-Positive Advanced Esophageal Squamous Cell Carcinoma

Cited by 2 publications

References 26 publications

Biomarkers for Early Detection, Prognosis, and Therapeutics of Esophageal Cancers

Biomarkers for Early Detection, Prognosis, and Therapeutics of Esophageal Cancers

Chemoimmunotherapy for esophageal squamous cell carcinoma—Summary and discussion of recent clinical trials

Contact Info

Product

Resources

About